Project Details
Description
A Multi-Center Randomized Double Blind Placebo-Controlled Phase III trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Theraapy following Allogeneic Transplant for patients with FLT3-ITD AML
| Status | Active |
|---|---|
| Effective start/end date | 5/1/17 → 5/30/22 |
Funding
- National Marrow Donor Program